In:
Neurodegenerative Diseases, S. Karger AG, Vol. 18, No. 1 ( 2018), p. 38-48
Abstract:
Adult-onset neurological disorders are caused and influenced by a multitude of different factors, including epigenetic modifications. Here, using an ELISA kit selected upon careful testing, we investigated global 5-methylcytosine (5-mC) levels in sporadic and familial amyotrophic lateral sclerosis (sALS and fALS), spinocerebellar ataxia types 1 and 2 (SCA1 and SCA2), Huntington’s disease, Friedreich’s ataxia, and myotonic dystrophy type 1. We report a significant elevation in global 5-mC levels of about 2–7% on average for sALS ( 〈 i 〉 p 〈 /i 〉 & #x3c; 0.01 [F(1, 243) = 9.159, 〈 i 〉 p 〈 /i 〉 = 0.0027]) and various forms of fALS along with SCA1 ( 〈 i 〉 p 〈 /i 〉 & #x3c; 0.01 [F(1, 83) = 11.285], 〈 i 〉 p 〈 /i 〉 = 0.0012) and SCA2 ( 〈 i 〉 p 〈 /i 〉 & #x3c; 0.001 [F(1, 122) = 29.996, 〈 i 〉 p 〈 /i 〉 = 0.0001]) when compared to age- and sex-matched healthy controls. 〈 i 〉 C9orf72 〈 /i 〉 expansion carrier ALS patients exhibit the highest global 5-mC levels along with 〈 i 〉 C9orf72 〈 /i 〉 promoter hypermethylation. We failed to measure global 5-hydroxymethylcytosine (5-hmC) levels in blood, probably due to the very low levels of 5-hmC and the limitations of the commercially available ELISA kits. Our results point towards a role for epigenetics modification in ALS, SCA1, and SCA2, and help conclude a dispute on the global 5-mC levels in sALS blood.
Type of Medium:
Online Resource
ISSN:
1660-2854
,
1660-2862
Language:
English
Publisher:
S. Karger AG
Publication Date:
2018
detail.hit.zdb_id:
2126858-7
Bookmarklink